Image de couverture de livre

Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Lisa Proost, Stijn Lambrecht, Mattias Hofmans, Ciel De Vriendt, Marijn Speeckaert, Carolien Bonroy, Barbara Denys, Sander De Bruyne
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	HemaSphere
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
par: Mwanasha H. Merrill, et autres
Publié: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
par: Martijn W. C. Verbeek, et autres
Publié: (2025)

NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
par: Emma Kroeze, et autres
Publié: (2024)

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
par: Aida Santaolalla, et autres
Publié: (2026)

Immunophenotypic abnormality quantification refines multiparameter flow cytometry‐based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission
par: Calvin M. Le, et autres
Publié: (2026)

Monitoring outcomes in patients treated by ATMPs
par: Kostas Konstantopoulos
Publié: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
par: Daniel Mazza Matos
Publié: (2026)

Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel
par: Audrey Couturier, et autres
Publié: (2024)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
par: Eirini Katodritou, et autres
Publié: (2025)

De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
par: Peter Johnstone, et autres
Publié: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
par: Suzana da Silva‐Benedito, et autres
Publié: (2026)

High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine
par: Francesca Tiso, et autres
Publié: (2025)

Circulating tumor‐associated and neoantigen‐specific endogenous T cells in children treated for B‐acute lymphoblastic leukemia
par: Eliane Huwiler, et autres
Publié: (2025)

Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
par: Sibylle Cocciardi, et autres
Publié: (2025)

Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials
par: Celia González‐Gil, et autres
Publié: (2025)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
par: Benjamin A. Derman, et autres
Publié: (2025)

Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)
par: Jean‐Michel Cayuela, et autres
Publié: (2025)

Correction to “Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials”
Publié: (2026)

Parents' perception of treatment‐related toxicity in children treated according to the NOPHO ALL2008 protocol for acute lymphoblastic leukemia
par: Nina Mogensen, et autres
Publié: (2024)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
par: Maeve A. O'Reilly, et autres
Publié: (2024)

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN‐iMDS‐Flow Working Group in an independent cohort of patients with MDS
par: Coen R. Veenstra, et autres
Publié: (2025)

Diagnosis without consent: A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
par: Richard J. Buka
Publié: (2026)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
par: Thomas C. Wiemers, et autres
Publié: (2026)

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM‐2 study
par: Stefano Luminari, et autres
Publié: (2026)

Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy
par: Gunnar Cario, et autres
Publié: (2025)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
par: Gian Matteo Rigolin, et autres
Publié: (2024)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
par: Idanna Innocenti, et autres
Publié: (2024)

Risk of central nervous system versus systemic relapse in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: What should we focus on?
par: Magdalena Klanova, et autres
Publié: (2025)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
par: Jean Galtier, et autres
Publié: (2025)

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
par: Riccardo Bomben, et autres
Publié: (2024)

Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in KMT2A‐rearranged acute leukemia
par: Qirui Zhang, et autres
Publié: (2024)

A RiboCancer cell line panel reveals that CLL‐associated Rps15 mutations translationally rewire transcription through codon‐specific tRNA accommodation defects
par: Anaïs Astier, et autres
Publié: (2026)

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
par: Wassilis S. C. Bruins, et autres
Publié: (2025)

Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia
par: Rosita Del Prete, et autres
Publié: (2024)

Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis
par: Hélène F. E. Gleitz, et autres
Publié: (2025)

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
par: Sophie Le Grand, et autres
Publié: (2025)

Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: A mixed‐methods, prospective cohort study
par: Elisabeth Dovern, et autres
Publié: (2025)

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
par: Claudia Bellofiore, et autres
Publié: (2026)

Prognostic value of measurable residual disease in high‐risk MDS after intensive chemotherapy in HOVON‐SAKK studies
par: Coen R. Veenstra, et autres
Publié: (2026)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
par: Cristina De Ramón, et autres
Publié: (2024)